The American Liver Foundation

The American Liver Foundation recently hosted its annual Salute to Excellence gala, honoring those who have made an outstanding contribution to biotechnology and medical innovation. The Salute, a black tie awards event, has been held annually for more than twelve years, with dramatic growth every year.

Sandy Bohl, Jack Denneboom

The Liver Foundation’s mission is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.

Graham Allan, Becky Frank, Joanne Riskin, Bon Riskin

This year’s honorees were:

Alan C. Mendelson: A partner in the Silicon Valley office of Latham & Watkins LLP, a leading global law firm, Mendelson is Co-Chair of the firm’s Emerging Companies Practice Group. For the more than quarter century that he has advised emerging companies throughout the United States, Alan Mendelson has earned a reputation as one of the industry’s brightest and most innovative legal advisors. From the landmark incorporation of Amgen in 1980 to his current work with cutting-edge emerging and public life science companies, Mendelson has played an influential role in the “life cycle” of emerging companies — helping to bring ground-breaking drugs and medical devices to market, while also nurturing the growth of companies that have evolved into industry leaders. Mr. Mendelson currently serves as a member of the Board of Trustees of the UC Berkeley Foundation, as President of the California Alumni Association Board of Directors and as a member of the Board of Overseers Visiting Committee of Harvard Law School. He received his B.A. degree from the University of California, Berkeley in 1969 and his J.D. degree from Harvard University in 1973.

Hal Barron, Carol Cunningham

Hal Barron, M.D., has been appointed Executive Vice President, Head of Global Development: Oncology, Inflammation, and Virology at Genentech. Dr. Barron is also the Chief Medical Officer in the United States responsible for the products of the combined portfolio of Roche and Genentech in the U.S. In addition, Dr. Barron is a member of Genentech’s Drug Safety and Pharma Executive Committees. Dr. Barron’s academic positions include Associate Adjunct Professor of Epidemiology and Biostatistics and Associate Clinical Professor of Medicine/Cardiology at the University of California, San Francisco. Prior to joining Genentech, Dr. Barron received his Bachelor of Science in physics from Washington University in St. Louis, his Medical Degree from Yale University and completed his training in medicine and cardiology at the University of California San Francisco.

Becky Frank, Michelle Flatley

Harry Greenberg, M.D. is the Joseph D. Grant Professor of Medicine and Microbiology and Immunology and the Senior Associate Dean for Research at Stanford University School of Medicine. He is also a staff physician at the Palo Alto VA hospital. Dr. Greenberg is a member of a variety of scholarly societies, governmental committees and editorial boards. He is the past President of the American Society of Virology, a consultant for a variety of vaccine manufacturing companies and the director of Stanford’s National Institutes of Health’s (NIH) funded Clinical and Translational Science Awards. He has been an active NIH funded investigator for over 30 years during which time his studies have focused primarily on viruses that infect the GI tract, liver or respiratory tree. Dr. Greenberg received his BA in History from Dartmouth College in 1966. He received his M.D. from Columbia College of Physicians and Surgeons in 1970.

Fred Dorey, Deepa Pakianathan
Harry Greenberg, Alan Mendelson, Hal Barron
Nancy Ascher, John Roberts, Deepa Pakianathan , David Cheung
Saira Ramasastry, Chris Morace
Tyler Atwood, Lynn Edminster, Jennifer Bienaime, Deepa Pakianathan
Natalie Bzowej, Vivek Huilgol

“I am proud of the vital work of the Liver Foundation and honored to present this award to such highly deserving recipients. The leadership of these individuals has exponentially increased our visibility and allowed us to further build our research program — designed to award seed grants in support of building careers in liver research, ” said Graham Allan, Division Board Chair, American Liver Foundation. Estimated to affect more people than those living with diabetes (type 1 and type 2) and all cancers combined, liver disease affects an estimated 30 million Americans. Due to perceptions about the common causes of liver disease, the public often turn away for fear of association; neglecting to obtain the preventative information they need to make better informed decisions about their health. Visit the website at www.liverfoundation.org for more information.